EverBridge Group is a leading MedTech company in Asia, committed to providing high-quality and affordable products to global customers.

We engage in extensive collaboration with outstanding companies around the world, establishing a bridge for medical technology innovation between Asia and the world, and providing better treatment options for doctors and patients worldwide.

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” (The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines.)